Merck inks another deal to test Keytruda combinations
This article was originally published in Scrip
Executive Summary
Merck & Co continued its streak of immuno-oncology dealmaking in a strategic clinical research collaboration with the University of Texas MD Anderson Cancer Center to test Keytruda (pembrolizumab) in combination with other treatments in three specific tumor types.